Amanote Research
Register
Sign In
Atezolizumab Combo Approved for PD-L1–positive TNBC
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2019-038
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
March 20, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
PD-L1 Inhibitor Improves Survival in TNBC
Cancer Discovery
Oncology
NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status
Pneumologie
Medicine
Pulmonary
Respiratory Medicine
Pembro Ups Survival in PD-L1–positive HNSCC
Cancer Discovery
Oncology
NSCLC: Zwei Positive Studien Zu PD-L1-Hemmer
Im Focus Onkologie
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
Forensic Medicine
Pathology
Histology
Application of Anti-Pd-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer
Effective Pharmacotherapy
Macrophage PD-L1 Strikes Back: PD-1/PD-L1 Interaction Drives Macrophages Toward Regulatory Subsets
Advances in Bioscience and Biotechnology
Prostate Cancer Responds to Anti–PD-1–ctla4 Combo
Cancer Discovery
Oncology
Immune Profiling of Malignant Pleural Mesothelioma by Flow Cytometry Identifies Distinct T-Cell Activation and Exhaustion Phenotypes in PD-L1 Positive Versus PD-L1 Negative Tumors
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
